6pc4 › Citations

Structure-Activity Relationship Study of Novel 6-Aryl-2-benzoyl-pyridines as Tubulin Polymerization Inhibitors with Potent Antiproliferative Properties.

Chen H, Deng S, Wang Y, Albadari N, Kumar G, Ma D, Li W, White SW, Miller DD, Li W
J Med Chem 63 827-846 (2020)
Cited: 11 times
EuropePMC logo PMID: 31860298

Abstract

We recently reported the crystal structure of tubulin in complex with a colchicine binding site inhibitor (CBSI), ABI-231, having 2-aryl-4-benzoyl-imidazole (ABI). Based on this and additional crystal structures, here we report the structure-activity relationship study of a novel series of pyridine analogues of ABI-231, with compound

Reviews - 6pc4 mentioned but not cited (1)

  1. Molecular interactions at the colchicine binding site in tubulin: An X-ray crystallography perspective. Wang J, Miller DD, Li W. Drug Discov Today 27 759-776 (2022)


Articles citing this publication (10)

  1. Design, Synthesis, and Biological Evaluation of Stable Colchicine-Binding Site Tubulin Inhibitors 6-Aryl-2-benzoyl-pyridines as Potential Anticancer Agents. Chen H, Deng S, Albadari N, Yun MK, Zhang S, Li Y, Ma D, Parke DN, Yang L, Seagroves TN, White SW, Miller DD, Li W. J Med Chem 64 12049-12074 (2021)
  2. A Phase Ib/II Study of Sabizabulin, a Novel Oral Cytoskeleton Disruptor, in Men with Metastatic Castration-resistant Prostate Cancer with Progression on an Androgen Receptor-targeting Agent. Markowski MC, Tutrone R, Pieczonka C, Barnette KG, Getzenberg RH, Rodriguez D, Steiner MS, Saltzstein DR, Eisenberger MA, Antonarakis ES. Clin Cancer Res 28 2789-2795 (2022)
  3. X-ray Crystallography-Guided Design, Antitumor Efficacy, and QSAR Analysis of Metabolically Stable Cyclopenta-Pyrimidinyl Dihydroquinoxalinone as a Potent Tubulin Polymerization Inhibitor. Banerjee S, Mahmud F, Deng S, Ma L, Yun MK, Fakayode SO, Arnst KE, Yang L, Chen H, Wu Z, Lukka PB, Parmar K, Meibohm B, White SW, Wang Y, Li W, Miller DD. J Med Chem 64 13072-13095 (2021)
  4. Tubulin Inhibitors: A Chemoinformatic Analysis Using Cell-Based Data. López-López E, Cerda-García-Rojas CM, Medina-Franco JL. Molecules 26 2483 (2021)
  5. SB226, an inhibitor of tubulin polymerization, inhibits paclitaxel-resistant melanoma growth and spontaneous metastasis. Deng S, Banerjee S, Chen H, Pochampally S, Wang Y, Yun MK, White SW, Parmar K, Meibohm B, Hartman KL, Wu Z, Miller DD, Li W. Cancer Lett 555 216046 (2023)
  6. Nanoformulation design and therapeutic potential of a novel tubulin inhibitor in pancreatic cancer. Bhattarai RS, Kumar V, Romanova S, Bariwal J, Chen H, Deng S, Bhatt VR, Bronich T, Li W, Mahato RI. J Control Release 329 585-597 (2021)
  7. Sabizabulin, a Potent Orally Bioavailable Colchicine Binding Site Agent, Suppresses HER2+ Breast Cancer and Metastasis. Krutilina RI, Hartman KL, Oluwalana D, Playa HC, Parke DN, Chen H, Miller DD, Li W, Seagroves TN. Cancers (Basel) 14 5336 (2022)
  8. The Tubulin Inhibitor VERU-111 in Combination With Vemurafenib Provides an Effective Treatment of Vemurafenib-Resistant A375 Melanoma. Cui H, Wang Q, Miller DD, Li W. Front Pharmacol 12 637098 (2021)
  9. Discovery of N-(3,4-Dimethylphenyl)-4-(4-isobutyrylphenyl)-2,3,3a,4,5,9b-hexahydrofuro[3,2-c]quinoline-8-sulfonamide as a Potent Dual MDM2/XIAP Inhibitor. Wu Z, Gu L, Zhang S, Liu T, Lukka PB, Meibohm B, Bollinger JC, Zhou M, Li W. J Med Chem 64 1930-1950 (2021)
  10. Colchicine-Binding Site Agent CH-2-77 as a Potent Tubulin Inhibitor Suppressing Triple-Negative Breast Cancer. Deng S, Krutilina RI, Hartman KL, Chen H, Chen H, Parke DN, Wang R, Mahmud F, Ma D, Lukka PB, Meibohm B, Seagroves TN, Miller DD, Li W. Mol Cancer Ther 21 1103-1114 (2022)


Quick links